Jazz Pharmaceuticals plc Overview
Pro stress-test →Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. The company targets unmet medical needs in rare and serious diseases.
Strategic Profile
Pro stress-test →Jazz wants to balance its neuroscience and oncology franchises with its existing sleep and rare-disease portfolio. In November 2025, Jazz announced positive results from its Phase 3 trial for Ziihera, a potential treatment for advanced gastroesophageal cancer. The company is executing a diversified strategy with recent approvals (Modeyso for brain cancer) and pipeline advances supporting growth.
Competitive Landscape
Pro stress-test →Gilead, Regeneron Pharmaceuticals, Harmony Biosciences Holdings, Amgen, and Akari Therapeutics are among Jazz's 20 key competitors. Jazz competes in specialty pharma against larger integrated pharmas and pure-play specialty biotech. The company's differentiation lies in rare disease expertise and oncology pipeline depth, though faces pricing pressure and patent cliff risks typical of the sector.
Industry Context
Jazz Pharmaceuticals plc operates in Biopharmaceuticals / Specialty Pharma.
Key facts
Founded: 2003 · Headquarters: Dublin, Ireland · Revenue: $4.16B · Market cap: $10.1B